These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 30642824)

  • 41. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
    Elia AR; Caputo S; Bellone M
    Front Immunol; 2018; 9():1786. PubMed ID: 30108594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vasculitis associated with immune checkpoint inhibitors-a systematic review.
    Daxini A; Cronin K; Sreih AG
    Clin Rheumatol; 2018 Sep; 37(9):2579-2584. PubMed ID: 29923081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies.
    Komaki Y; Komaki F; Yamada A; Micic D; Ido A; Sakuraba A
    Clin Pharmacol Ther; 2018 Feb; 103(2):318-331. PubMed ID: 28118483
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal effects of immune checkpoint inhibitors.
    Izzedine H; Mateus C; Boutros C; Robert C; Rouvier P; Amoura Z; Mathian A
    Nephrol Dial Transplant; 2017 Jun; 32(6):936-942. PubMed ID: 28025384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
    Papouin B; Mussini C; De Martin E; Guettier C
    Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection-A Mini Comment on the 2018 Medicine Nobel Prize.
    Liu J; Pan W; Yang D
    Virol Sin; 2018 Dec; 33(6):467-471. PubMed ID: 30570713
    [No Abstract]   [Full Text] [Related]  

  • 48. Immune checkpoint inhibitor rechallenge in patients with immune-related myositis.
    Delyon J; Brunet-Possenti F; Leonard-Louis S; Arangalage D; Baudet M; Baroudjian B; Lebbe C; Hervier B;
    Ann Rheum Dis; 2019 Nov; 78(11):e129. PubMed ID: 30242031
    [No Abstract]   [Full Text] [Related]  

  • 49. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
    Brahmer JR; Lacchetti C; Schneider BJ; Atkins MB; Brassil KJ; Caterino JM; Chau I; Ernstoff MS; Gardner JM; Ginex P; Hallmeyer S; Holter Chakrabarty J; Leighl NB; Mammen JS; McDermott DF; Naing A; Nastoupil LJ; Phillips T; Porter LD; Puzanov I; Reichner CA; Santomasso BD; Seigel C; Spira A; Suarez-Almazor ME; Wang Y; Weber JS; Wolchok JD; Thompson JA;
    J Clin Oncol; 2018 Jun; 36(17):1714-1768. PubMed ID: 29442540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
    Sweis RF; Luke JJ
    Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunological and clinical implications of immune checkpoint blockade in human cancer.
    Kim HD; Park SH
    Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The immune checkpoint inhibitors: where are we now?
    Webster RM
    Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
    [No Abstract]   [Full Text] [Related]  

  • 54. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Not Available].
    Caux C; Bay JO
    Bull Cancer; 2018 Dec; 105 Suppl 1():S1-S2. PubMed ID: 30595190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer immunotherapy of patients with HIV infection.
    Gonzalez-Cao M; Martinez-Picado J; Karachaliou N; Rosell R; Meyerhans A
    Clin Transl Oncol; 2019 Jun; 21(6):713-720. PubMed ID: 30446984
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.
    Bang A; Wilhite TJ; Pike LRG; Cagney DN; Aizer AA; Taylor A; Spektor A; Krishnan M; Ott PA; Balboni TA; Hodi FS; Schoenfeld JD
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):344-351. PubMed ID: 28463153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
    Diesendruck Y; Benhar I
    Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
    Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
    J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of Checkpoint Inhibition in Localized Bladder Cancer.
    Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
    Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.